Emerik Osterlund, Postdoctoral Fellow in Gastrointestinal Medical Oncology at MD Anderson Cancer Center, shared a post on X:
“Tumor Board Tuesday
High specificity of ctDNA supports intensified follow-up to catch relapse early .
If MRD trials are available, consider enrollment — an opportunity to eradicate disease before overt metastases emerge.”
Aparna Raj Parikh shared a post by Emerik Osterlund, adding:
“This is the goal, right therapies to cure more (and also de escalate) but early escalation data has not yet shown the way (ALTAIR, DYNAMIC3) but trials, trials, trials.
Many underway! ”
More posts featuring Emerik Osterlund on OncoDaily.